NRF2 Mediates Therapeutic Resistance to Chemoradiation in Colorectal Cancer through a Metabolic Switch by O’Cathail, SM et al.
antioxidants
Article
NRF2 Mediates Therapeutic Resistance to Chemoradiation in
Colorectal Cancer through a Metabolic Switch
Sean M. O’Cathail 1,*, Chieh-Hsi Wu 2, Rachael Thomas 3, Maria A. Hawkins 4, Tim S. Maughan 5
and Annabelle Lewis 6


Citation: O’Cathail, S.M.; Wu, C.-H.;
Thomas, R.; Hawkins, M.A.;
Maughan, T.S.; Lewis, A. NRF2
Mediates Therapeutic Resistance to
Chemoradiation in Colorectal Cancer
through a Metabolic Switch.
Antioxidants 2021, 10, 1380. https://
doi.org/10.3390/antiox10091380
Academic Editors: Lidija Milković
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Abstract: Radiation resistance is a significant clinical problem in rectal cancer treatment, the mechanisms
of which are poorly understood. NRF2 signalling is known to contribute to chemo/radioresistance in
some cancers, but its role in therapeutic resistance in colorectal cancer (CRC) is unexplored. Using
siRNA and CRiSPR/Cas9 isogenic CRC cell lines, we investigated the effect of the knockdown and
upregulation of the NRF2 pathway on chemo-radiosensitivity. Poly (A) enriched RNA sequencing
and geneset enrichment analysis (GSEA) were carried out on both sensitive and resistant cell models
for mechanistic insights. Finally, a cohort of rectal patient samples was profiled to understand the
clinical relevance of NRF2 signalling. Radioresistant cell lines were significantly radiosensitised by
siRNA knockdown (SW1463, SER10 1.22, ANOVA p < 0.0001; HT55, SER10 1.17, ANOVA p < 0.01),
but not the (already) radiosensitive HCT116. The constitutive activation of NRF2 via a CRISPR
Cas9 NFE2L2 mutation, E79K, induced radioresistance in HCT116 (SER10 0.71, ANOVA, p < 0.0001).
GSEA demonstrated significant opposing metabolic dependencies in NRF2 signalling, specifically,
the downregulation of amino acid and protein synthesis with low levels of NRF2 and upregulation
with over expression. In a clinical cohort of 127 rectal patients, using a validated mRNA signature,
higher baseline NRF2 signalling was associated with incomplete responses to radiation higher final
neoadjuvant rectal (NAR) score (OR 1.34, 95% C.I. 1.01–1.80, LRT p-value = 0.023), where high NAR
indicates poor radiation response and poor long-term prognosis. This is the first demonstration of
NRF2-mediated radiation resistance in colorectal cancer. NRF2 appears to regulate crucial metabolic
pathways, which could be exploited for therapeutic interventions.
Keywords: NRF2; radiation; metabolism; therapeutic resistance
1. Introduction
Chemoradiation is the standard of care for all patients with locally advanced rectal
cancer. Some patients respond poorly with little or no tumour regression [1], highlighting
the need to better understand contributing factors. NRF2 is a potent transcription factor
that plays a responsive role in cell protection against oxidative and electrophilic stress, as
well as metabolic regulation. In unstressed conditions, NRF2 is targeted for ubiquitination
by KEAP1 resulting in its degradation. The constitutive activation of NRF2 signalling can
occur by a number of distinct mechanisms, including somatic mutation of key regulators
KEAP1/NFE2L2, methylation of KEAP1 and direct activation by oncogenes KRAS, BRAF
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and c-MYC [2–4]. This allows NRF2 to function in an ‘oncogene’ fashion, promoting
survival, resisting radiation and dysregulating metabolism [5,6]. In fact, NRF2 has been
linked, either directly or indirectly, to all of the Hallmarks of Cancer [7].
NRF2 pathway expression has been shown to contribute to radioresistance in many
tumour types, in particular, lung cancer [8,9], SCC head and neck [10,11], oesophageal [12]
and pancreas [13], and its mechanism extensively investigated [14]. However, its role
in therapeutic resistance in CRC is poorly understood, in spite of the fact that the NRF2
pathway can be overexpressed in CRC through a variety of the outlined mechanisms [15].
This oversight is probably due to the fact that the rate of somatic mutation in both KEAP1
and NFE2L2 is low in CRC [16] in comparison to the previously studied tumour types.
Nevertheless, in a PanCancer analysis, the level of NRF2 pathway signalling is higher
than would be expected (in multiple tumour types, including colon and rectal tumours)
given this low mutation rate, suggesting that activation within tumours occurs, warranting
further investigation [17].
In this study, we investigated the effects of downregulating and overactivating NRF2
on both chemo- and radio-resistance in colorectal cancer models in vitro, identified the key
cellular pathways involved, and assessed the clinical relevance of NRF2 pathway activation
in a large clinical rectal cancer dataset.
2. Materials and Methods
2.1. Cell Culture
Cell lines, SW146 (rectal adenocarcinoma), HT55 (rectal adenocarcinoma) and HCT116
(colon adenocarcinoma), were obtained from the American Type Culture Collection (ATCC)
and the European Collection of Authenticated Cell Cultures (ECACC). All cells were
maintained in Dulbecco’s modified Eagles Medium (DMEM) supplemented with 10% FBS
and 1% penicillin streptomycin.
2.2. NRF2 Disrupted Cell Line Models
Isogenic cell lines HCT116E79K+ and parental HCT116WT were obtained from Hori-
zon Discovery® (Cambridge Research Park, Cambridge, CB25 9TL, UK). The missense
mutation was confirmed by Sanger sequencing and FISH was used to confirm that the
NFE2L2 locus was otherwise intact (see supplementary methods). The upregulation of
NRF2 target genes was confirmed by quantitative RT-PCR with Taqman probes (Applied
Biosystems, Life Technologies Ltd, Paisley, PA4 9RF, UK).
NFE2L2 siRNAs and non-targeting controls (Ambion®, see Supplementary Materials
for sequences) were transfected into HCT116 and SW1463 using Lipofectamine 2000 (final
concentration 1.8 µM, Invitrogen®) and HT55 using INTERFERin-HTS (final concentration
20 nM, VWR). Knockdown of NRF2 and target genes was confirmed by quantitative
RT-PCR with Taqman probes (Applied Biosystems).
2.3. Assessment of Radio and Chemotherapeutic Resistance
Clonogenic assays were carried out on siRNA transfected cells irradiated at 2, 4 and
6 Gy using a caesium-137 irradiator (Gamma Service GSR D1) and incubated for 14–25 days
for colony formation. Fixed colonies stained with 0.5% (w/v) crystal violet were counted
digitally using GELCOUNT™ (Oxford Optronix) software. Statistical analysis and plotting
of clonogenic survival curves was performed using the ‘CFAssay’ package in R [18].
Cytotoxic drugs were obtained from Sigma (oxaliplatin), Flurochem (5-flurouracil)
and Sellekchem (SN-38). Cell viability to cytotoxic drugs was determined using MTS assay
(CellTiter® 96R AQueous Non-Radioactive Cell Proliferation Assay), performed as per the
manufacturer’s instruction. Analysis was carried out using the R drc package [19].
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2.4. RNA Sequencing and Analysis
Poly(A) enriched mRNA libraries were prepared using the Truseq stranded mRNA
system and sequenced on a HiSeq4000 (Illumina) according to the manufacturer’s pro-
tocols. Differential expression analysis was performed in R with both ‘DESeq2’ [20] and
‘edgeR’ [21] to ensure robustness. Main analysis and plots were generated from edgeR data.
GSEA was carried out against the hallmark gene sets, Reactome pathways and KEGG
pathways from the Molecular Signatures Database v6.2 [22,23] using the ‘fgsea’ pack-
age [24]. The ranked gene list was compared to the a priori defined gene sets and the
curated geneset NFE2L2.v2, for a total of 1000 permutations. An FDR < 0.1 was used to
highlight significant pathways of enrichment. RNA sequencing data were deposited to the
Gene Expression Omnibus under accession number GSE136011.
2.5. Rectal Cancer Cohort and Statistical Association of NRF2 Signature with NAR Score
Patients’ samples were obtained through the MRC Stratified Colorectal cancer (S:CORT)
collaboration and approved by the East of England-Cambridge South Research Ethics Com-
mittee (NHS Health Research Authority) (REC reference 15/EE/0241). Following RNA
extraction from biopsy specimens, samples were profiled on Xcel microarray as per the
manufacturer’s instructions. Raw data were normalised and batch corrected to generate an
expression matrix. NRF2 pathway expression was measured using a previously published
36-gene signature [25]. Univariate and multivariate ordinal logistic regression models were
built, the null hypothesis being (H0) that it would not provide any explanatory power for
NAR scores. The likelihood ratio test (LRT) was employed to test the hypothesis. (Full
details available in supplementary methods).
3. Results
3.1. Changes in NRF2 Signalling Mediate Radiation Response
Knockdown of NRF2 with RNAi resulted in a significant decrease in NRF2 signalling
in three CRC cell lines as assessed by validated NRF2 transcriptional targets, NQO1 and
HMOX1 [26], as surrogates of pathway perturbation [27] (Supplementary Figure S1a–c).
Significant radiosensitisation was observed in NRF2-depleted SW1463 (SER10 1.22, ANOVA
p < 0.0001) and HT55 (SER10 1.17, ANOVA p < 0.01) cell lines, with no effect on HCT116
(Figure 1a–c), and was consistent across three independent NRF2 siRNAs (Supplementary
Figure S1d). HCT116 is intrinsically a radiosensitive cell line [28]. Compared to SW1463
and HT55, it also had the lowest level of NRF2 activity (Supplementary Figure S1e). This
suggested a possible threshold effect for radioresistance, where an a priori degree of
overactivation of NRF2 signalling is required for knockdown to produce radiosensitisation.
To investigate further, we used HCT116 CRISPR/Cas9 isogenic wild type and NFE2L2
mutant models. Karyotyping, FISH and Sanger sequencing confirmed that both isogenic
HCT116 lines were diploid for NFE2L2 and the presence of a single heterozygous missense
mutation at position 235 of NFE2L2 in HCT116 E79K+ cells (Figure 1d). The resulting
mutant NRF2 protein has weak affinity for KEAP1, resulting in cytoplasmic accumulation
(Supplementary Figure S1f) of NRF2. Elevated levels of NRF2 protein and downstream
activation were confirmed by mRNA levels of NRF2 transcriptional targets (Supplementary
Figure S1g). HCT116 E79K+ demonstrated increased radioresistance compared to wild
type (SER10 0.71, ANOVA, p < 0.0001) (Figure 1e), confirming that the overactivation of
NRF2 signalling induces radioresistance. MTS cell viability assays were performed for
5-FU, SN-38 and Oxaliplatin to identify cross resistance with common radiosensitising
chemotherapies. Relative to HCT116WT, HCT116 E79K+ showed significantly increased
cell viability to 5-FU and SN-38 but not oxaliplatin (Figure 1f).




Figure 1. NRF2 knockdown increases radiosensitivity in resistant cell lines and introduction of NRF2 mutation induces
radioresistance in sensitive cells. (a–c) Cell survival curves demonstrating significant radiosensitisation in SW1463 and HT55,
but not HCT116; (d) FISH analysis of NFE2L2 locus and Sanger sequencing of CRISPR HCT116 isogenic cell lines confirming
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diploid status of NFE2L2 and point mutation (G > A) at position 235; (e) clonogenic assay and resultant cell survival curve
demonstrating increased radioresistance in E79K+ mutant cell line relative to wild type; (f) MTS cell viability assays with
common colorectal chemotherapeutics—5-Flurouracil, Irinotecan, Oxaliplatin—demonstrating increased resistance to both
5-Flurouracil and Irinotecan.
3.2. NRF2 Signalling Changes Significantly Alter Amino Acid Metabolism
To better understand the NRF2 signalling changes produced in the in vitro colorectal
models, which in turn could explain the phenotypic changes in radiation responses, whole
transcriptomic profiling RNA sequencing and gene set enrichment analysis (GSEA) were
performed on the RNAi and isogenic mutant models. Using the NFE2L2.v2 signature from
the molecular signatures database to verify that NRF2 signalling had been altered, the
RNAi model showed significant negative enrichment for the NFE2L2 targets (ES-0.35; NES-
1.66; p < 0.01). By contrast, the NRF2 E79K + mutant model showed significant enrichment
for the NFE2L2 targets (ES 0.31; NES 1.36; p = 0.015) (Figure 2a,b). Global analysis using
the Hallmarks genesets highlighted the significant downregulation of metabolism in the
NRF2 KD model and metabolic upregulation with NRF2 overactivation (Figure 2c,d).
Further phenotypic exploration undertaken using the Kyoto Encyclopaedia of Genes and
Genomes (KEGG) pathways and REACTOME pathways also showed significant changes in
metabolic processes, in particular, pathways involved in amino acid synthesis and protein
metabolism (Figure 2c,d, Supplementary Tables S1 and S2).
The enriched, opposing effects on amino acid metabolism was of particular interest
and prompted further investigation as a potential mechanism. One striking overlap of the
volcano plots and the top 20 DE genes under both conditions was the presence of asparagine
synthetase (ASNS), a significantly downregulated target in the knockdown model (logFC-
0.96, FDR 5.66 × 10–34) and a significantly upregulated target in the NRF2 mutant model
(logFC 1.46, FDR 2.72 × 10–170). ASNS encodes an enzyme which catalyses the conversion
of aspartate and glutamine, to asparagine and glutamate, respectively, in an ATP-dependent
reaction. Recent data also suggest that ASNS acts in conjunction with mTOR signalling to
promote protein and nucleotide synthesis and cell proliferation [29]. GSEA analysis using
the MSigDB C6 Oncogenic signatures set confirmed mTOR expression was shared and
highly enriched in both models, with negative enrichment following NRF2 KD (NES-1.77,
FDR p value = 0.036) and positive enrichment in NRF2 E79K + MUT cells (NES 1.97, FDR
p value = 0.006) (Supplementary Figure S2a,b; Supplementary Tables S3 and S4).
To understand which genes were mediating these changes, all significantly (FDR < 0.01)
differentially expressed genes from the NRF2 KD and NRF2 E79K MUT models were
examined for overlap. A total of 216 genes were shared, of which 141 had opposing logFC
changes (Supplementary Tables S5 and S6) and demonstrated opposing enrichments for
metabolic processes (Figure 3). Functional relationship analysis of these genes using the
STRING database [30] revealed a highly significant interaction network, with ASNS at
the hub (Supplementary Figure S3). The number of interacting nodes was 117, higher
than the predicted number of 35 for a set of 141 genes, with a protein–protein interaction
enrichment p-value < 1 × 10–16. The top biological process (GO) enrichments were GO:
0006521 ‘cellular amino acid metabolic process’ (19/308; FDR p-value 7.83 × 10–9) and GO:
0006418 ‘tRNA aminoacylation of protein translation’ (9/48; FDR p-value 4.4 × 10–7). The
interaction network highlighted three key metabolic domains—amino acid metabolism and
transport, tRNA acetylation and mTOR signalling—which correspond to the interactions
seen in the KEGG GSEA analysis (Figure 3c).




Figure 2. Downregulation and upregulation of NRF2 signalling result in opposing effects on tumour metabolism, particularly
amino acid and protein metabolism. (a) GSEA enrichment plot for NFE2L2 targets in the ranked logFC of genes in the
siRNA SW1463 model showing significant downregulation of NRF2 signalling; (b) GSEA enrichment plot for NFE2L2 targets
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in the ranked logFC of genes in the HCT116 E79K+ model showing significant upregulation of NRF2 signalling; (c,d) GSEA
enrichment plots the most significant Hallmark gene signatures, highlighting an opposing effect on metabolism; (e,f) KEGG
pathway analysis supports the significant opposing effects, with a particular focus on amino acid and protein metabolism;




Figure 3. Changes in NRF2 signalling alternatively regulates a conserved group of genes responsible
for metabolic processes. (a) Venn diagram showing the shared group of genes in different states of
NRF2 activation; (b) heatmaps of relative change in expression (z-score) of shared genes, with key
metabolic genes highlighted; (c) GSEA KEGG pathway analysis of conserved group of shared genes
demonstrating significant enrichment for amino acid and protein metabolism.
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3.3. NRF2 Signalling Associated with Worse Response to Radiotherapy In Vivo
To explore the role of NRF2 signalling in clinical radioresistance, mRNA profiling of a
cohort of pre-treatment rectal biopsies specimens was undertaken. NRF2 signalling was
derived using a previously validated NRF2 36 gene colorectal mRNA signature (Supple-
mentary Table S7). A total of 127 patients were included with characteristics summarised
in Table 1.
Table 1. Rectal cohort characteristics (N = 127).
N %
Gender Male 77 61
Female 50 39




cN 0 63 50
1 51 40
2 13 10




ypN 0 101 80
1 21 16
2 5 4
NAR tertiles Low (0–8) 44 34
Intermediate (8–16) 56 44
High (>16) 27 21
Pathological
Response * Complete 33 27
Incomplete 90 73
* Four patients not formally graded for pathological response.
Radiation response in patients can be measured in several ways. One of the most
common is pathological response, which can be easily binarized into complete (no visible
tumour remaining) and incomplete (any visible tumour remaining). A more novel approach
is the neoadjuvant rectal (NAR) score [31], which is calculated from clinical variables of
tumour (T) and nodal (N) stage. It captures how much a tumour has regressed and whether
viable tumour deposits remain in lymph nodes following radiation treatment. NAR is a
validated surrogate of the true clinically relevant endpoint of disease-free survival (DFS)
and overall survival (OS) [31,32] and is the primary endpoint in the ongoing NRG-GI002
platform phase II trial (NCT02921256).
Preoperative mean NRF2 expression was significantly higher in those with an incom-
plete response to radiation (Wilcoxon rank sum, p = 0.027) (Figure 4a). The rate of complete
response is highest among patients in the lowest tertile of NRF2 expression and lowest in
those in the highest tertile (Figure 4b).







Figure 4. High NRF2 expression in baseline biopsies is associated with worse tumour response in patients (N = 123).
(a) Boxplot comparing mean NRF2 signature expression between patients who achieve a complete pathological response
and those who have residual disease following radiation; (b) count table showing a significantly higher proportion of
patients with the highest tertile of NRF2 signature expression have a worse response to radiation; (c) ordinal logistic
regression plots for NRF2 expression predicting NAR score. Upper row: Probability of an NAR > 16. As NRF2 expression
increases, the odds of a high NAR score increase. The effects of including clinical nodal stage from the MRI on the model
are also shown. Clinical nodal stage is the only clinical factor that is not part of the NAR score. Node positivity at baseline
and high expression of NRF2 signature has much greater odds of a high NAR score. Lower row: Probability of NAR < 8. As
NRF2 expression increases, the odds of low NAR score decrease. Adjustments for cN stage are also shown. (L, M, H are
tertiles of NRF2 signature expression where L = lowest/bottom tertile; M = median tertile; H = highest tertile) (* signifies
p < 0.05).
Higher NRF2 signalling was also associated with higher NAR (Figure 4c). In the
ordinal regression model, this relationship was statistically significant with an odds ratio
of 1.34 (95% C.I. 1.01–1.80, LRT p-value = 0.023). After adjusting for the effect of clinical N
stage, higher NRF2 signature expression corresponded to higher NAR scores (OR = 1.35,
95% C.I. 1.00–1.81, LRT p-value = 0.0403). In clinical terms, the model demonstrates that
for patients with high NRF2 activation, as measured by the chosen RNA-based signature,
the odds of a high NAR score—a poor response—at the end of neoadjuvant therapy were
much increased.
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4. Discussion
Here, we present the first demonstration that aberrant NRF2 signalling is an important
determinant of radiation-induced cell death in colorectal cancer cells. Although previ-
ous work has established that the upregulation of NRF2 signalling acts as a mediator of
radioresistance in some cancer types [8,11], its effect in CRC had been overlooked and
its role underinvestigated. The cell lines SW1463 and HT55, which are known to be ra-
dioresistant [28], had higher levels of NRF2 signalling and were significantly sensitised
by NRF2 inhibition in a reproducible fashion. Inhibition had no effect on radiosensitive
cell lines. However, it was possible to induce radioresistance in the sensitive HCT116 cell
line by CRISPR Cas9 constitutive activation of the NRF2 pathway. Previous work has
also suggested that increased NRF2 leads to chemoresistance [33–35], confirmed by our
colorectal drug sensitivity screen. Taken together, these data provide proof of concept
that NRF2 may have a role to play in mediating therapeutic resistance in vivo. The idea
that baseline, constitutive activation could play a key role in radiation response was ex-
plored in a large rectal cancer biopsy cohort. Using a validated RNA-based signature of
NRF2 signalling, we further demonstrate that higher baseline levels of NRF2 signalling
contribute to a radioresistant phenotype in rectal cancer patients treated with neoadjuvant
chemoradiotherapy. These results highlight the real-world clinical relevance of NRF2 in
the therapeutic resistance of colorectal cancer.
From a mechanistic perspective, these data and the other recent literature [13,36], sug-
gest that NRF2 exerts regulatory control over a complex amino acid metabolic biogenesis
program, possibly through co-ordination with mTOR, to increase therapeutic resistance. At
a basic level, ionising radiation produces reactive oxygen species which damage DNA. To
repair this damage, cells require adequate amounts of raw materials—nucleotides. ‘Switch-
ing off’ NRF2 shuts down key metabolic pathways leading to an inability to synthesise
nucleotides and proteins necessary to repair cellular damage, plausibly resulting in more
effective cell kill from radiation. A permanently ‘switched on’ NRF2 signalling cascade
produces the opposite effect (Figure 5). ASNS may be the main mechanism by which
the metabolic effect of NRF2 is transduced within the cell, but its role requires further
elucidation, which is ongoing within our group.
The inherent novelty of the work herein implies that more elaboration is required
before being translated into a clinical setting. As a canonical pathway, which functions
as a transcription regulator, it is a possible therapeutic target, with some success already
seen in directly inhibiting NRF2 [6,34]. Off target effects are a concern, however, with
difficulties targeting NRF2 with direct, specific inhibitors [37]. More recent data have
suggested that in order to be active and promote transcription, NRF2 must be de-glycated
by Fructosamine-3-kinase (FN3K)—a protein kinase [38]. Sanghvi et al. suggest this may
present an opportunity for therapeutic intervention. Another elegant solution may come
from exploiting the metabolic shift seen in NRF2 over expressing cancers. A metabolic
requirement for glutaminolysis in KEAP1-NRF2-mutant lung adenocarcinoma has been
observed, and treatment with two glutaminase inhibitors greatly reduced growth poten-
tial [9]. CB839, a glutaminase inhibitor, is currently being used in two phase I/II trials in
CRC (NCT03263429; NCT02861300). Interestingly, the former requires KRAS WT patients,
while the latter mandates PIK3CA mutant patients. It has been suggested that NRF2
pathway overexpression is a mechanism of acquired tolerance in the PI3K-RAS mutant
cancers [27,39] so one may expect the latter study to be enriched for high NRF2 expression
and thus more likely to show benefit. Other attractive future strategies could include
using an NRF2 biomarker, histological [40] or transcriptomic [25], for enriching studies of
metabolic interventions.
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Figure 5. Metabolic ‘switch’ model in response to changes in NRF2. Upregulation of NRF2 facilitates an anabolic process of
nucleotide production, mTOR signalling which increases cell proliferation and ribosomal biogenesis. It also impairs the
cell’s ability to maintain redox homeostasis. Downregulation of NRF2 produces the reverse effect, abrogating many essential
cell mechanisms required for cell survival, crucial to survival following radiation induced damage. The cell circuit diagram
summarises the changes produced by the relative change in gene expression (green = upregulated; red = downregulated).
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5. Conclusions
CRC can now be counted among the increasing number of tumours in which NRF2 is
a relevant signalling pathway for therapeutic resistance. As its role in metabolic regulation
is increasingly understood, translational efforts to exploit the dependency for therapeutic
advantage should be encouraged.
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